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ABSTRACT  
   
 
Alzheimer’s disease (AD) is the most common type of dementia, affecting one in 
nine people age 65 and older. One of the most important neuropathological characteristics 
of Alzheimer’s disease is the aggregation and deposition of the protein beta-amyloid. Beta-
amyloid is produced by proteolytic processing of the Amyloid Precursor Protein (APP). 
Production of beta-amyloid from APP is increased when cells are subject to stress since 
both APP and beta-secretase are upregulated by stress. An increased beta-amyloid level 
promotes aggregation of beta-amyloid into toxic species which cause an increase in 
reactive oxygen species (ROS) and a decrease in cell viability. Therefore reducing beta-
amyloid generation is a promising method to control cell damage following stress. 
The goal of this thesis was to test the effect of inhibiting beta-amyloid production 
inside stressed AD cell model. Hydrogen peroxide was used as stressing agent. Two 
treatments were used to inhibit beta-amyloid production, including iBSec1, an scFv 
designed to block beta-secretase site of APP, and DIA10D, a bispecific tandem scFv 
engineered to cleave alpha-secretase site of APP and block beta-secretase site of APP. 
iBSec1 treatment was added extracellularly while DIA10D was stably expressed inside cell 
using PSECTAG vector. Increase in reactive oxygen species and decrease in cell viability 
were observed after addition of hydrogen peroxide to AD cell model. The increase in stress 
induced toxicity caused by addition of hydrogen peroxide was dramatically decreased by 
simultaneously treating the cells with iBSec1 or DIA10D to block the increase in beta-
amyloid levels resulting from the upregulation of APP and beta-secretase.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Alzheimer’s Disease Background 
Alzheimer’s disease (AD) is the most common form of dementia and the sixth 
leading cause of death in the United States (Gaugler et al., 2013). It is a neurodegenerative 
disease that deteriorates the brain, affecting memory, speech, and mobility. Prevalence of 
this disease can be seen through the painting of an artist William Utermohlen. Figure 1.1 
below shows a collection of his self-portraits. Utermohlen was diagnosed with AD in 1995 
and as the disease progresses, his face in his paintings becomes harder and harder to 
discern. 
 
Figure 1.1. Self-portraits of artist William Utermohlen, diagnosed with AD on 1995 
(http://www.williamutermohlen.org) 
  2 
No cure is currently available for Alzheimer’s disease. Treatments are given to slow 
down disease progression. Cholinesterase inhibitors like Donepezil and Galantamine are 
prescribed to slow down breakdown of acetylcholine receptors (Selkoe, 2001). Another 
type of medication prescribed is Memantine, used to regulate activity of glutamate which 
is a messenger chemical involved in memory and learning (Bond et al., 2012). Although 
these medications can be used to slow down AD progression, they are ineffective as long 
term treatment for the disease.  
About 5.2 million people in the United States have Alzheimer’s disease, costing the 
nation $203 billion in treatment and care; number of people with the disease is estimated 
to double by 2020 and triple by 2050 (Hebert et al., 2013). Moreover, an estimated 17.7 
billion hours of unpaid care were given to Alzheimer’s patients by family and friends, 
valued at more than $220 billion (Hurd et al., 2013). These facts highlight the importance 
of a more effective treatment for Alzheimer’s disease. 
 
1.2 Alzheimer’s Disease Neuropathology 
Compared to normal brain, Alzheimer’s disease brain shows shrinkage; these 
shrinkage are especially more visible in the cerebral cortex and hippocampus region. 
Studies have also shown significant neuronal loss in several area of the brain, including 
hippocampus (West et al., 1994). Figure 1.2 below shows the difference between brain cell 
of normal and AD patient. Two very important neuropathological characteristics of AD are 
the deposition of beta-amyloid (Aβ) plaques and neurofibrillary tangles of 
hyperphosphorolated tau protein (Tiraboschi et al., 2004).  
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Figure 1.2. Brain cells of normal and AD patient. Neurofibrillary tangles of 
hyperphosphorolated tau protein and amyloid plaques of Aβ protein can be seen in brain 
of AD patient (Weiner et al., 2006). 
 
1.2.1. Beta-amyloid plaques 
Plaques in AD patients form as deposits between neurons from the aggregation of 
Aβ protein (Selkoe, 2001). They are spherical in shape and are usually found in limbic 
brain regions like hippocampus and amygdala (LaFerla et al., 2005). Beta-amyloid, 
typically a 40/42 amino acid protein, is formed from processing of amyloid precursor 
protein (APP) with the 42 amino acid long Aβ more prone to aggregation. These beta-
amyloid when aggregates form beta sheet structures. Amyloid plaques also form in normal 
brain; however, plaques formation in AD brain is significantly higher (Tomlinson et al., 
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1997). What cause plaques formation is still unclear, whether it is due to irregular 
processing of APP or improper accumulation of Aβ. 
 
1.2.2. Neurofibrillary Tangles 
Another hallmark of Alzheimer’s disease is the intracellular formation of 
neurofibrillary tangles. These neurofibrillary tangles are composed of 
hyperphosphorolated tau protein (Iy et al., 1998). Tau are proteins whose primary function 
is to maintain structural stability of microtubules. AD patients show hyperphosphorolation 
of tau proteins, resulting in dissociation of microtubules and self-assembly of 
hyperphosphorolated tau. Braak staging is sometimes used to group the disease progression 
into six different stages based on the amount of neurofibrillary tangles in the brain (Braak 
et al., 1991). 
 
1.3. Alzheimer’s Disease Pathogenesis 
 While the cause of Alzheimer’s disease is still unknown, there are three main 
hypothesis to explain the disease using its hallmark: the cholinergic hypothesis, the 
amyloid hypothesis, and the tau hypothesis (Tanzi et al., 2005). 
 
1.3.1. The cholinergic hypothesis 
 Acetylcholine is a neurotransmitter in both peripheral and central nervous system; 
it plays an important role in conscious awareness, attention, working memory, and 
additional mnemonic processes. Acetylcholine is synthesized from choline and acetyl-CoA 
by the enzyme choline acetyltransferase (Feldberb, 1945). The cholinergic hypothesis 
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started in 1970s when study of postmortem AD brains show reduced activity of choline 
acetyltransferase in hyppocampus and cerebral cortex (Davies et al., 1976; Perry et al., 
1977); it states that cognitive decline in Alzheimer’s patient is a result of loss of cholinergic 
function.  
 Many AD drugs have been developed based on this hypothesis. 
Acetylcholinesterase inhibitors are used to inhibit acetylcholinesterase enzyme from 
breaking down acetylcholine, thus increasing the level of acetylcholine receptors in the 
brain. Currently, four acetylcholinesterase inhibitors are FDA approved and prescribed for 
AD patients; they are tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon), and 
galantamine (Razadyne). While these medication can be used to slow down disease 
progression and provide symptomatic benefit, they cannot stop or reverse the disease 
progression. 
 
1.3.2. The amyloid hypothesis 
 Two main neuropathology hallmark of Alzheimer’s disease are the extracellular 
beta-amyloid plaques and intracellular neurofibrillary tangles of hyperphosphorolated tau 
protein. The amyloid hypothesis states that neurodegeneration in Alzheimer’s disease is 
caused by accumulation of Aβ inside the brain. These accumulation are due to irregular 
processing of APP and improper clearance of beta-amyloid from the brain. Previously, the 
amyloid hypothesis states that the fibrillar Aβ are the toxic species causing cell death and 
hyperphosphorolation of tau protein (Hardy, 1992; Selkoe, 2001). However, recent studies 
have shown that oligomeric Aβ are the toxic species triggering cell apoptosis in AD brain 
(Walsh et al., 2002; Sierks et al., 2011). 
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 Aβ is formed by cleavage of Amyloid Precursor Protein (APP) by beta and gamma 
secretases (figure 1.3). β-site APP cleaving enzyme-1 (BACE-1) has been reported to be 
the predominant beta secretase enzyme responsible during APP processing through 
amyloidogenic pathway (Vassar et al., 1999; Yan et al., 1999). After monomeric Aβ is 
formed through APP processing, it aggregates, forming oligomeric species (Glass et al., 
2010). Further aggregation of these oligomeric species result in the formation of amyloid 
plaques, one of the hallmarks of AD.  
 
Figure 1.3. Proteolytic processing of APP. Non-amyloidogenic pathway of APP processing 
involves cleaving by α-secretase followed by γ-secretase, resulting in formation of 
membrane-bound protein p3. Amyloidogenic pathway involves cleaving by β-secretase 
instead of α-secretase, followed again by γ-secretase, yielding insoluble beta-amyloid 
protein (Boddapati et al., 2011). 
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Many drugs are currently developed based on the amyloid hypothesis; while many 
are in clinical trials, none of these drugs are FDA approved and prescribed for AD patients. 
One way to reduce amyloid in the brain is by clearing excess Aβ; Crenezumab is a 
monoclonal antibody currently in phase 2 clinical trial licensed to Genentech that was 
engineered to bind aggregated form of Aβ and clear them from the brain (Panza et al., 
2014). Another way is to manipulate APP processing and reduce Aβ formation; this can be 
done by promoting cleavage of APP at alpha site, reducing APP cleavage at beta site, and 
reducing APP cleavage at gamma site. ASec1A is an example of proteolitic antibody 
designed to cleave APP at alpha site and iBSec1 is an example of monoclonal antibody 
against beta-amyloid cleaving enzyme 1 site of APP (Kasturirangan et al., 2009; Boddapati 
et al., 2011). Many research are also currently done in order to break and prevent 
aggregation of Aβ protein. Preventing accumulation of Aβ aggregates is a promising 
therapeutics for treatment against Alzheimer’s disease. 
 
1.3.3. The tau hypothesis 
 Tau hypothesis states that neurodegeneration in AD is caused by abnormalities in 
tau protein. Hyperphosphorolation of tau protein in AD cause dissociation of microtubules 
and formation of helical filaments and eventually neurofibrillary tangles (Iqbal et al., 1986; 
Alonso et al., 1994). Dissociation of microtubules leads to impaired axonal transport and 
synaptic transmission, contributing to neurodegeneration in Alzheimer’s disease 
(Grundke-Iqbal et al., 1986). While neurofibrillary tangles are hallmark of AD, they also 
occur in several other neurological disorder, including subacute sclerosing panencephalitis 
and progressive supranuclear palsy (De la Torre et al., 2011; Muresan et al., 2009). 
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1.4. Oxidative stress and Alzheimer’s disease 
 Increase in oxidative stress can be seen in brain of Alzheimer’s disease patients 
compared to normal brain (Pratico, 2008). Buildup of oxidative stress lead to activation of 
c-Jun N-terminal kinase and p38, eventually leading to caspase-3 activity causing 
programmed cell death to occur (Marques et al., 2003). Oxidative stress is linked with beta-
amyloid induced neurotoxicity, tau pathology, mitochondria dysfunction, and metal 
dyshomeostasis.   
Many studies have been done on beta-amyloid and its relation with oxidative stress 
(Mattson, 1997). In vitro experiment in mammalian cell line showed that beta-amyloid 
addition increases reactive oxygen species (Behl et al., 1994). Consistently, experiments in 
AD transgenic mouse models upregulating beta-amyloid processing show increase in 
oxidative damage to the brain (Matsuoka et al., 2001; Smith et al., 1998; Apelt et al., 2004).  
Moreover, numerous studies have also shown that oxidative stress promotes beta-amyloid 
production. In vivo studies in transgenic mice model overexpressing APP show increase in 
beta-amyloid production as result of elevated oxidative stress and glucocorticoid stress 
hormone (Nishida et al., 2006; Green et al., 2006). Beta amyloid generation leads to 
increase in oxidative stress, thus leading to further beta-amyloid production; this creates a 
cycle that promotes the initiation and progression of Alzheimer’s disease.  
 Oxidative stress is also linked with mitochondria dysfunction, metal 
dyshomeostasis, and tau pathology in AD. Biopsies from AD brain shows damage and 
reduction of mitochondria along with oxidative damage marked by 8-hydroxyguanosine 
and nitrotyrosine (Hirai et al., 2001). Abnormal level of copper, zinc, and iron in the brain 
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have also been observed in AD patient (Deibel et al., 1996); moreover, these metals are 
found inside amyloid deposits (Lovell et al., 1998). Reports have shown that reduction of 
these transition metals by beta-amyloid generate hydrogen peroxide and increase oxidative 
stress (Opazo et al., 2002; Rottkamp et al., 2001). Several studies have also linked oxidative 
stress with hyperphosphorolation of tau protein. P38 mitogen-activated protein kinase has 
been shown to phosphorolate tau in-vitro (Goedert et al., 1997). In hippocampal and 
cortical region of AD brain, activated p38 is found coimmunoprecipitated with 
hyperphosphorolated tau, suggesting that oxidative stress might be involved in tau 
pathology (Zhu et al., 2000).  
 
 
Figure 1.4. Sequence of event leading to apoptosis due to beta-amyloid generation 
(Marques et al., 2003). 
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1.5. Diagnosis and treatment 
 Currently, postmortem confirmational diagnosis of Alzheimer’s disease is done 
through brain biopsy (Mckhann et al., 1984). Prior to death, presumed diagnosis can be 
done by measuring the amount of beta amyloid and tau protein in cerebrospinal fluid 
combined with PET scan, MRI, and other imaging methods (Prvulovic et al., 2011; Hampel 
et al., 2004; Risacher et al., 2009). However, AD pathogenesis occurs long before symptom 
starts to occur. Given the cost for treatment of AD and the predicted increase in AD cases 
within the next several years, more effective diagnosis methods and treatment must be 
developed. 
 Current AD treatment has been aimed to slow the disease progression. Primary 
drugs prescribed for AD are acetylcholinesterase inhibitors used to slow down the 
breakdown of acetylcholine receptors. However, these medications are ineffective in 
reversing or halting the disease progression, giving the need for a more effective treatment. 
Due to the current popularity of the amyloid hypothesis, many drugs are currently 
developed to reduce Aβ production and accumulation in the brain. Reducing Aβ production 
can be done by cleaving alpha-site of APP, blocking beta-site of APP, and blocking 
gamma-site of APP. 
The use of single chain fragment variable (scFv) in therapeutics holds considerable 
promise. scFvs consist of the heavy and light chain of an antibody’s antigen binding region 
linked together (figure 1.5). Just like antibodies, scFvs can also be engineered to be 
monoclonal and specific to the antigen they recognize. However, they are much smaller in 
size, allowing for better tissue penetration (Yokota et al., 1992); moreover, scFvs are less 
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immunogenic compared to antibodies because they do not have the fragment crystallizable 
region that cause inflammatory reactions (Miller et al., 2005). 
 
Figure 1.5. Illustration of immunoglobin and its antibody derivatives, fragment antigen 
binding (Fab) and single chain fragment variable (scFv) (Hairul Bahara et al., 2013). 
 
1.6. Research objectives 
 Oxidative stress has been shown to accelerate AD progression both in-vitro and in-
vivo. For this thesis, hydrogen peroxide is used to induce oxidative stress in AD cell model. 
iBSec1, a single chain fragment variable, and DIA10D, a bispecific tandem scFv, have 
been previously characterized and shown to reduce Aβ production (Boddapati et al., 2011; 
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Boddapati et al., 2012). The main objective of this thesis is to analyze the effect of 
inhibiting Aβ production using iBSec1 and DIA10D in stressed AD cell model.  
 This thesis consists of four chapters. The first chapter provides background 
information on Alzheimer’s disease and the motivation behind this project. The second 
chapter deals with testing iBSec1 against stressed AD cell model. Chapter three presents 
the effect of DIA10D expression in stressed cell model of AD compared to non-AD cell 
model. Finally, chapter four provides summary and recommendation for future works. 
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Chapter 2 
Effect of blocking beta-site of APP on stress induced toxicity in  
cell model of Alzheimer’s disease 
 
Vicky Suryadi, Shanta Boddapati, and Michael Sierks 
 
Chemical engineering, School for Engineering of Matter, Transport, and Energy,  
Arizona State University, Tempe, AZ 85287-6106 
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2.1. Introduction 
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States 
(Gaugler et al., 2013). It is a neurodegenerative disease that deteriorates the brain, affecting 
memory, speech, and mobility. According to the 2013 AD Facts and Figures, there are 
about 5.2 million people diagnosed with AD in the United States at a cost of over $200 
billion (Gaugler et al., 2013). 
 Two very important neuropathological characteristics of AD are the deposition of 
beta-amyloid (Aβ) plaques and neurofibrillary tangles of hyperphosphorolated tau protein. 
Aβ is formed by cleavage of Amyloid Precursor Protein (APP) by beta and gamma 
secretases. β-site APP cleaving enzyme-1 (BACE-1) has been reported to be the 
predominant beta secretase enzyme responsible during APP processing through 
amyloidogenic pathway (Vassar et al., 1999; Yan et al., 1999). After monomeric Aβ is 
formed through APP processing, it aggregates, forming oligomeric species (Glass et al., 
2010). Further aggregation of these oligomeric species result in the formation of amyloid 
plaques, one of the hallmarks of AD (Hardy et al., 2002). Oligomeric forms of Aβ have 
been reported to be neurotoxic and are responsible for loss of neurons in AD patients (Gong 
et al., 2003; Glabe, 2008; Lesne et al., 2006). Depositions of Aβ can be reduced by 
promoting cleavage of APP at alpha site, reducing APP cleavage at beta site, and inhibiting 
Aβ aggregation.  
 Many studies have investigated the effect of stress on AD progression. Green et al 
(2006) showed that after injection of glucocorticoids, hormone upregulated by stress, Aβ 
and hyperphosphorolated tau inside AD mouse model increased. In other studies, stress 
induced by hydrogen peroxide has been shown to increase Aβ level in cell lines expressing 
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APP (Misonou et al., 2000; Shen et al., 2008). Increase in Aβ due to stress has been shown 
to correlate with decrease in cell viability as well as increase in both caspase-3 activity and 
reactive oxygen species (ROS) (Misonou et al, 2000; Casley et al., 2002; Reddy, 2006). 
Thus, ROS, caspase-3 activity, and cell viability are good measurements of stress-induced 
toxicity in cell models. 
iBSec1 is a recombinant antibody fragment that selectively blocks BACE-1 
processing of APP by binding the APP substrate as opposed to blocking the enzyme active 
site (Boddapati et al., 2011).  Previous study on Chinese Hamster Ovaries (CHO) cell lines 
stably transfected with cDNA encoding mutant human APP751 (7PA2) showed that 
treatment of cells with 1.3 uM iBSec1 reduces both intracellular and extracellular Aβ by 
more than 40% (Boddapati et al., 2011). Here, we show that iBSec1 effectively protects 
cells from stress induced toxicity.   
 
2.2. Materials and methods 
 
2.2.1. Purification of iBSec1 scFv 
 IBSec1 was previously subcloned into PPNL9 expression vector and inserted into 
YVH10 strain of yeast. Expression and purification of iBSec1 were done as reported by 
Boddapati et al. (2011).  
 
2.2.2. Cell culture 
7PA2 cell line was a gift from Dr. Dennis Selkoe (Harvard Medical School, Boston, 
MA). Cells were grown in Dulbecco Modified Eagle Medium (Invitrogen, Grand Island, 
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CA) containing 10% fetal bovine serum (Invitrogen, Grand Island, NY), 2mM L-
Glutamine (Invitrogen, Grand Island, NY), and 1% penicillin streptomycin (Invitrogen, 
Grand Island, NY). For selection purpose, 150 μg/mL of G-418 was added to media 
(Sigma-Aldrich, St. Louis, MO).  
 
2.2.3. Reactive oxygen species (ROS) assay 
2,7-dichlorodihydrofluoroscein diacetate (DCFH-DA) (Sigma-Aldrich, St. Louis, 
MO)  was used to measure the amount of reactive oxygen species inside cells. When 
DCFH-DA diffuses into cells, it is deacetylated to form 2,7-dichlorodihydrofluoroscein 
(DCFH). In presence of reactive oxygen species, DCFH is oxidized to form highly 
fluorescent 2,7-dichlorodihydrofluoroscein (DCF). 
7PA2 cells were plated at density of 105 cells per mL in a 96-well plate. After 48 
hours, the media was changed and treatments using hydrogen peroxide and antibodies were 
done. After 24 hour treatments, media was aspirated and new media containing 100 μM 
DCFH-DA was added. The media was aspirated after 45 minutes of exposure to DCFH-
DA and amount of reactive oxygen species was measured using spectrophotometer by 
reading fluorescence at 480nm/535 nm.  
 
2.2.4. Cell viability assay 
Cell viability was measured using the XTT cell proliferation assay kit (ATCC, 
Manassas, VA). After entering the cell membrane, XTT is reduced into formazan by 
breaking apart the quaternary tetrazole ring. Reduction into formazan can be visibly seen 
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by a color change from slightly yellow to bright orange or quantified by reading the 
absorbance at 475nm.  
7PA2 cells were plated at density of 105 cells per mL in a 96-well plate. After 48 
hours, the media was changed and treatment using hydrogen peroxide and antibodies were 
done. After 24-hour treatments, the media was aspirated and new media containing XTT 
solution (2:1 ratio) was added. Absorbance was measured at 490nm (specific absorbance) 
and 650nm (non-specific absorbance/background) after 3 hours incubation at 37 0C. 
 
2.3. Results and discussion 
 
2.3.1. Purification of iBSec1 scFv 
After expression, iBSec1 was purified using immobilized metal affinity 
chromatography as described in the materials and methods section. Western blot showed 
35 kD band, size of iBSec1 scFv, inside 50mM, 100 mM and 500 mM elutions (figure 2.1). 
100 mM and 500 mM imidazole elutions were combined and dialyzed using 10kD 
Macrosep column. Protein concentration was then quantified using bicinchoninic acid 
assay. 
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Figure 2.1. Western blot image of iBSec1 purification. Membrane shows in order from left 
to right: molecular weight marker, 50 mM imidazole elution, 100 mM imidazole elution, 
and 500 mM imidazole elution.  
 
2.3.2. Reactive oxygen species assay 
Hydrogen peroxide treatment has been reported to increase reactive oxygen species 
inside cell lines expressing APP. 7PA2 cells were stressed using hydrogen peroxide and 
iBSec1 was added to inhibit Aβ production. According to Boddapati et al., 1.3 μM of 
iBSec1 showed highest protection and Aβ inhibition in 7PA2 cells (2011). To show 
concentration dependent protection, 130 nM iBSec1 was also used for the experiment. 
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Figure 2.2. ROS levels for 7PA2 cells treated with different concentration of hydrogen 
peroxide and iBSec1. n=3. Error bars: +/-1 SE. 
 From figure 2.2, it can be seen that addition of hydrogen peroxide as oxidative 
stress to the cell increases ROS generation. Furthermore, co-incubation of cells with 
iBSec1 showed a concentration decrease in ROS. At concentration of 1,500 μM, decrease 
in ROS can be seen due to cell death (see figure 2.4 for cell viability result). Because 
DCFH-DA dye used for ROS measurement diffuses into cell and reacts with ROS 
generated intracellularly, ROS signals needed to be normalized to cell viability. 
0
20
40
60
80
100
120
140
160
180
0 500 1000 1500
R
O
S 
[%
 c
o
n
tr
o
l]
Hydrogen peroxide [μM]
no scFv 130 nM iBSec1 1.3 uM iBSec1
  20 
 
Figure 2.3. ROS levels for 7PA2 cells treated with different concentration of hydrogen 
peroxide and iBSec1 normalized to cell viability. n=3. Error bars: +/-1 SE. 
 Figure 2.3 showed ROS generation normalized to cell viability. P values were also 
computed using one-way ANOVA and recorded in table 2.1. Again, increase in ROS 
generation was seen with increasing concentration of hydrogen peroxide used. While 
addition of 500 μM hydrogen peroxide did not show a significant increase in ROS, addition 
of 1 and 1.5 mM showed statistically significant increase in ROS generation (P<0.05). 
Moreover, concentration dependent decrease in ROS generation was observed with 
addition of iBSec1. With the exception of 1.3μM treatment of iBSec1 on unstressed 7PA2 
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cells, addition of iBSec1 to unstressed and cells stressed with 500 μM hydrogen peroxide 
did not show statistically significant reduction in ROS signals (P<0.05). However, addition 
of iBSec1 to cells incubated with 1 mM and 1.5 mM hydrogen peroxide showed significant 
decrease in ROS generation. Addition of hydrogen peroxide in cell lines expressing APP 
has been reported to increase ROS generation and Aβ production (Misonou et al., 2000; 
Shen et al., 2008). Here, we showed that ROS generation can be downregulated by 
inhibiting Aβ production. 
Group 1 Group 2 significance 
H2O2 [μM] scFv [nM] 
H2O2 
[μM] 
scFv 
[nM] (p<0.05) 
0 0 
500 0 0.26691171 
1000 0 0.03283433 
1500 0 0.00152889 
0 0 
0 130 0.1462256 
0 1300 0.03439308 
500 0 
500 130 0.07610944 
500 1300 0.06271206 
1000 0 
1000 130 0.01812285 
1000 1300 0.02290752 
1500 0 
1500 130 0.01441448 
1500 1300 0.00394039 
 
Table 2.1. One way ANOVA analysis of ROS signal. 
 
2.3.3. Cell viability assay 
Accumulation of reactive oxygen species results in caspase-3 activation leading to 
programmed cell death, thus reduction in cell viability. Cell viability of 7PA2 cells treated 
with hydrogen peroxide and iBSec1 was measured using XTT kit.  
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Figure 2.4. Cell viability for 7PA2 cells treated with different concentration of hydrogen 
peroxide and iBSec1. n=3. Error bars: +/-1 SE. 
Figure 2.4 shows that cell viability of 7PA2 cells started to decrease with addition of 1 mM 
hydrogen peroxide. Addition of 1.5 mM hydrogen peroxide decreased cell viability further 
to 65%. One way ANOVA showed statistical significant decrease in cell viability with 
addition of 1 and 1.5 mM hydrogen peroxide. Addition of iBSec1 showed significant 
concentration dependent increase in cell viability (P<0.05) in stressed and unstressed cells 
with the exception of 130 nM addition of iBSec1 to cells incubated with 1.5 mM hydrogen 
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peroxide. Results showed that iBSec1 effectively reduce stress induced toxicity in 7PA2 
cell line.  
Group 1 Group 2 significance 
H2O2 [uM] 
scFv 
[nM] H2O2 [uM] 
scFv 
[nM] (p<0.05) 
0 0 
500 0 0.544276 
1000 0 0.001674 
1500 0 0.000030 
0 0 
0 130 0.001134 
0 1300 0.000202 
500 0 
500 130 0.004836 
500 1300 0.000356 
1000 0 
1000 130 0.000169 
1000 1300 0.000252 
1500 0 
1500 130 0.148857 
1500 1300 0.000825 
 
Table 2.2. One way ANOVA analysis of cell viability.  
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3.1. Introduction 
 Alzheimer’s disease is one of the most prominent neurodegenerative disease 
associated with aging. It is the sixth leading cause of death in United States, affecting one 
in nine people age 65 and older (Gaugler et al., 2013). First reported case of AD came from 
a Bavarian psychiatrist, Dr. Alois Alzheimer in 1906; after the death of one of his patient, 
postmortem brain biopsy showed microscopic lesions of amyloid plaques and 
neurofibrillary tangles (Selkoe, 2011). Since then, many advancement have been made on 
AD; however, no effective treatment has been found for the disease.  
 Two neuropahological hallmarks of the disease are intracellular neurofibrillary 
tangles and extracellular amyloid plaques (Selkoe, 2001). Intracellular neurofibrillary 
tangles are composed primarily from hyperphosphorolated tau protein (Iqbal et al., 1986). 
Tau is a microtubule-binding protein used to stabilize axonal microtubule assembly. In AD, 
hyperphosphorolation of tau destabilizes microtubules, causing impairments in axonal 
transport and neuronal dysfunction (Grundke-Iqbal et al., 1986). Extracellular amyloid 
plaques are composed of beta-amyloid protein (Aβ). Aβ is formed from cleavage of 
amyloid precursor protein (APP) at beta and gamma site (figure 3.1). Aβ then aggregates, 
forming oligomeric species; oligomeric Aβ has been widely reported to be the primary 
toxic species causing neuronal death in AD (Walsh et al., 2002; Sierks et al., 2011). Further 
aggregation of oligomeric Aβ form fibrillar Aβ and amyloid plaques (Glass et al., 2010).  
Studies have been done on relation between Aβ and oxidative stress. Oxidative 
damage to the brain was reported in AD mouse models with upregulated beta-amyloid 
processing (Matsuoka et al., 2001; Smith et al., 1998; Apelt et al., 2004). In vitro, Aβ 
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addition to mammalian cell line B12 was also reported to increase reactive oxygen species 
(Behl et al., 1994). Many studies have also reported increase in Aβ as a result of oxidative 
stress. In vitro study in mammalian cell culture reported increase in Aβ production with 
addition of hydrogen peroxide as oxidative stress in mammalian cell lines expressing APP 
(Misonou et al., 2000). In vivo studies in transgenic mice model overexpressing APP show 
increase in beta-amyloid production as result of elevated oxidative stress and 
glucocorticoid stress hormone (Nishida et al., 2006; Green et al., 2006). Beta amyloid 
generation leads to increase in oxidative stress, thus leading to further beta-amyloid 
production; this creates a cycle that promotes the initiation and progression of Alzheimer’s 
disease.  
 DIA10D is a bispecific tandem scFv engineered to cleave APP at alpha-site and 
block beta-site of APP. Previous study shows stable transfection of DIA10D on human 
neuroglioma cell lines overexpressing APP reduces intracellular Aβ by 15% and 
extracellular Aβ by more than 50% while at the same time increasing production of 
neuroprotective sAPPα by 20% (Boddapati et al., 2012). When stably expressed in Chinese 
Hamster Ovaries (CHO) cell lines transfected with cDNA encoding mutant human APP751 
(7PA2), DIA10D effectively protects against stress induced toxicity.  
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Figure 3.1. Schematic showing APP processing. In non-amyloidogenic pathway, APP is 
cleaved by alpha and gamma-secretase enzyme, producing membrane-bound protein p3. 
In amyloidogenic pathway, APP is cleaved by beta and gamma-secretase enzyme, 
producing toxic Aβ (Boddapati et al., 2012). 
 
3.2. Materials and methods 
 
3.2.1. Plasmid purification 
 DIA10D was previously constructed, inserted into PSECTAG vector, and cloned 
into DH5α cell by Boddapati et al. (2012). Purification of DNA was done using EndoFree 
Plasmid Maxi Kit (Qiagen, Valencia, CA) according to manufacturer’s protocol. DNA 
concentration was obtained using NanoDrop 2000 (Thermo Scientific, Vernon Hills, IL).  
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3.2.2. Cell culture 
Two cell lines were used, Chinese Hamster Ovaries (CHO) (ATCC, Manassas, VA) 
and CHO cell line stably transfected with cDNA encoding mutant human APP751 (7PA2). 
7PA2 cell line were a gift from Dr. Dennis Selkoe (Harvard Medical School, Boston, MA). 
Cells were grown in Dulbecco Modified Eagle Medium (Invitrogen, Grand Island, CA) 
containing 10% fetal bovine serum (Invitrogen, Grand Island, NY), 2mM L-Glutamine 
(Invitrogen, Grand Island, NY), and 1% penicillin streptomycin (Invitrogen, Grand Island, 
NY). For selection purpose, 150 μg/mL of G-418 was added to 7PA2 cell media (Sigma-
Aldrich, St. Louis, MO). Cells were incubated in a 5% CO2 humidified incubator at 37
0C.  
 
3.2.2. Transfection and generation of stable cell lines 
 Transfection was performed using Fugene HD Transfection Reagent (Roche, 
Pleasanton, CA). CHO and 7PA2 cells were plated at density of 105 cells per mL in a 6-
well plate with 3 mL media. After reaching 50-70% confluency, transfection was 
performed. 3μg DNA and 6 μg reagent were incubated for 15 minutes in Dulbecco 
Modified Eagle Medium containing 2mM L-Glutamine and 1% penicillin streptomycin 
without serum. Media was aspirated from the wells, followed by addition of new media 
containing DNA and transfection reagent. Cells were then incubated at 370C for 6 hours, 
and media was replaced by complete media containing 10% serum. After 48 hours in 
complete media, zeocin was added at concentration of 400 μg/ml.  
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3.2.3. Fluorescence staining of cell 
 Cells were plated in at density of 105 cells per mL in a 6-well plate with 3 mL 
media. After 48 hours, media was aspirated and cells were fixed with 3.7% formaldehyde 
for 10 minutes at room temperature. Blocking was done using 3% FBS + 0.1% tween-20 
in PBS for 30 minutes followed by labeling using 1:200 dilution of monoclonal anti-c-Myc 
antibody (Sigma-Aldrich, St. Louis, MO) in PBS for 1 hour and 1:300 dilution of Alexa 
Fluor 488 goat anti-mouse FITC antibody (Life Technologies, Carlsbad, CA) in PBS for 
30 minutes in room temperature. Cells were visualized using a Zeiss AxioObserverD1 
fluorescence microscope. 
 
3.2.4. Western blot assay 
 SDS-PAGE sample buffer was added to cell supernatant at 1:1 ratio and boiled for 
5 minutes. Samples were then separated on a 15% SDS-PAGE gel and transferred onto 
nitrocellulose membranes. Membrane was then blocked using 5% milk in PBS for 2 hours 
in room temperature, followed by overnight incubation in 1:1000 dilution of monoclonal 
anti-c-Myc antibody in PBS overnight at 40C and 1:1000 dilution of goat anti-mouse HRP 
antibody (Sigma-Aldrich, St. Louis, MO). DAB chromogenic substrate was used to 
develop the blot as per manufacturer’s protocol. 
 
3.2.5. Reactive oxygen species (ROS) assay 
2,7-dichlorodihydrofluoroscein diacetate (DCFH-DA) (Sigma-Aldrich, St. Louis, 
MO)  was used to measure the amount of reactive oxygen species inside cells. Briefly, 100 
μl of cells were plated at density of 105 cells per mL in a 96-well plate. After 48 hours, the 
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media was changed and treatments using hydrogen peroxide and antibodies were done. 
After 24 hour treatments, media was aspirated and new media containing 100 μM DCFH-
DA was added. The media was aspirated after 45 minutes of exposure to DCFH-DA and 
amount of reactive oxygen species was measured using spectrophotometer by reading 
fluorescence at 480nm/535 nm.  
 
3.2.6. Cell viability assay 
Cell viability was measured using the XTT cell proliferation assay kit (ATCC, 
Manassas, VA). Briefly, 100 μl of cells were plated at density of 105 cells per mL in a 96-
well plate. After 48 hours, the media was changed and treatment using hydrogen peroxide 
and antibodies were done. After 24-hour treatments, the media was aspirated and new 
media containing XTT solution (2:1 ratio) was added. Absorbance was measured at 490nm 
(specific absorbance) and 650nm (non-specific absorbance/background) after 3 hours 
incubation at 37 0C. 
 
 
 
 
 
 
 
 
 
  31 
3.3. Results and discussion 
 
3.3.1. Fluorescence staining of cell 
 Fluorescence staining was done following transfection and addition of zeocin as 
resistance. It can be seen from figure 3.2 that CHO and 7PA2 showed no green 
fluorescence. Transfected CHO and 7PA2 with DIA10D showed green fluorescence, 
showing expression of protein with c-myc tag inside cell. 
  
  
Figure 3.2. Fluorescence cell staining of CHO (top left), CHO+DIA10D (top right), 
7PA2 (bottom left), and 7PA2+DIA10D (bottom right). 
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3.3.2. Western blot assay 
 Supernatant of cells were collected 48 hours after plating and ran on an SDS-PAGE 
gel. Samples were then transferred onto a nitrocellulose membrane and developed. Band 
corresponding 56 kDa protein can be seen in both transfected CHO and 7PA2 cells, 
showing full DIA10D expression.  
 
Figure 3.3. Western blot of supernatant after 48 hours. From left to right: marker, CHO, 
CHO+DIA10D, 7PA2, 7PA2+DIA10D, αPLB (+).  
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3.3.3. Reactive oxygen species assay 
 Transfected and non-transfected CHO and 7PA2 cells were plated and hydrogen 
peroxide was added. Intracellular reactive oxygen species was measured using DCFH-DA 
fluorescence dye after 24 hours treatment. ROS signals were normalized to cell viability. 
 
Figure 3.4. ROS for cells treated with different concentration of hydrogen peroxide 
normalized to cell viability. n=3. Error bars: +/-1 SE. 
 Significant difference can be seen from intracellular ROS between CHO and 7PA2 
cells (P<0.005). Higher ROS in 7PA2 cells are believed due to overexpression of APP 
leading to higher Aβ production. Increase in Aβ has been reported to increase oxidative 
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damage both in vivo and in vitro (Matsuoka et al., 2001; Smith et al., 1998; Apelt et al., 
2004; Behl et al., 1994). Moreover, increase in ROS can be seen with increasing treatment 
of hydrogen peroxide both in CHO and 7PA2 cells with 7PA2 showing a much higher 
increase in ROS generation. Higher ROS generation in 7PA2 cells is believed to be due to 
upregulated Aβ production; Aβ has been reported to increase oxidative stress while 
oxidative stress has been reported to upregulate Aβ production, creating a cycle that 
promotes Aβ production and neurotoxicity (Practico, 2008). 
 Significant decrease in ROS can be observed in 7PA2 cells stably expressing 
DIA10D compared to normal 7PA2 cells (P<0.05). We believe that decrease in ROS is due 
to both reduction in Aβ production and increase in sAPPα, which has been shown to be 
neuroprotective (Yang et al., 2007). Smaller effect of DIA10D on ROS generation was 
observed in CHO cells, with statistical significance (P<0.05) observed on untreated cells 
and stressed cells with 1, 2, and 2.5 mM hydrogen peroxide added. This is due to minimal 
amount of APP expression and processing by CHO cells, giving statistically insignificant 
effect of DIA10D. 
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Group 1 Group 2 significance 
H2O2 [uM] 
cell 
line 
H2O2 
[uM] cell line (p<0.05) 
0 CHO 
500 
CHO 
0.37362169 
1000 0.001499527 
1500 0.000310913 
2000 0.000825381 
2500 0.002643096 
0 7PA2 
500 
7PA2 
0.000195012 
1000 0.00053847 
1500 4.07088E-05 
2000 0.000174443 
2500 0.000121992 
0 
CHO 
0 
CHO+DIA10D 0.042067024 
CHO 7PA2 6.55369E-06 
7PA2 7PA2+DIA10D 0.047574079 
500 
CHO 
500 
CHO+DIA10D 0.143811658 
CHO 7PA2 0.000311991 
7PA2 7PA2+DIA10D 0.001364097 
1000 
CHO 
1000 
CHO+DIA10D 0.038890532 
CHO 7PA2 0.000155769 
7PA2 7PA2+DIA10D 0.001062011 
1500 
CHO 
1500 
CHO+DIA10D 0.024165425 
CHO 7PA2 5.61215E-05 
7PA2 7PA2+DIA10D 0.000166618 
2000 
CHO 
2000 
CHO+DIA10D 0.17926686 
CHO 7PA2 0.000186341 
7PA2 7PA2+DIA10D 0.000236544 
2500 
CHO 
2500 
CHO+DIA10D 0.040172425 
CHO 7PA2 0.000123099 
7PA2 7PA2+DIA10D 0.000151848 
 
Table 3.1. One way ANOVA analysis of ROS for CHO and 7PA2 cells. 
 
3.3.4. Cell viability assay 
Transfected and non-transfected CHO and 7PA2 cells were plated and hydrogen 
peroxide was added. Cell viability was measured using XTT kit following 24 hours 
treatment. 
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Figure 3.5. Viability for cells treated with different concentration of hydrogen peroxide. 
n=3. Error bars: +/-1 SE. 
 Cell viability of 7PA2 cells started to decrease with addition of 1.5 mM hydrogen 
peroxide while cell viability of CHO did not decrease until addition of 2.5 mM hydrogen 
peroxide. Moreover, no significant change of cell viability was observed with transfection 
of DIA10D into CHO cells with the exception of with treatment of 500 mM hydrogen 
peroxide. On the other hand, significant change in cell viability was observed in transfected 
7PA2 cells compared to non-transfected 7PA2 cells with 1.5, 2, and 2.5 mM treatment of 
hydrogen peroxide. This result is believed to be due to overexpression of APP in 7PA2 cell 
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line. DIA10D was reported to effectively reduce toxicity, reduce intra and extracellular Aβ 
production, and increase sAPPα production in cell line overexpressing APP (Boddapati et 
al., 2012). Data shows that DIA10D effectively protect 7PA2 cells from apoptosis due to 
oxidative stress while it does not protect CHO cells from oxidative stress.  
 
Group 1 Group 2 significance 
H2O2 [uM] cell line H2O2 [uM] cell line (p<0.05) 
0 CHO 
500 
CHO 
0.90730725 
1000 0.21988991 
1500 0.25506834 
2000 0.20776741 
2500 0.00123499 
0 
7PA2 500 
7PA2 
0.88145587 
  1000 0.51635167 
  1500 7.9403E-05 
  2000 1.5923E-07 
  2500 7.5294E-08 
0 
CHO 
0 
CHO+DIA10D 0.81296819 
CHO 7PA2 0.56394767 
7PA2 7PA2+DIA10D 0.06160497 
500 
CHO 
500 
CHO+DIA10D 0.00440084 
CHO 7PA2 0.35522036 
7PA2 7PA2+DIA10D 0.01457165 
1000 
CHO 
1000 
CHO+DIA10D 0.85498482 
CHO 7PA2 0.08691236 
7PA2 7PA2+DIA10D 0.28526818 
1500 
CHO 
1500 
CHO+DIA10D 0.39354347 
CHO 7PA2 9.5262E-05 
7PA2 7PA2+DIA10D 0.00067009 
2000 
CHO 
2000 
CHO+DIA10D 0.1940388 
CHO 7PA2 4.1813E-06 
7PA2 7PA2+DIA10D 1.4641E-05 
2500 
CHO 
2500 
CHO+DIA10D 0.57201129 
CHO 7PA2 4.6131E-07 
7PA2 7PA2+DIA10D 0.00673071 
 
Table 3.2. One way ANOVA analysis for cell viability of CHO and 7PA2 cells. 
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CHAPTER 4 
CONCLUSION AND FUTURE WORK 
 
4.1. Conclusion 
About 5.2 million people in the United States have Alzheimer’s disease, costing the 
nation $203 billion in treatment and care; number of people with the disease is estimated 
to double by 2020 and triple by 2050 (Hebert et al., 2013). Aβ upregulation leads to higher 
ROS generation, thus upregulating Aβ production further; this creates a cycle promoting 
initiation and progression of AD (Practico, 2008). Therefore, one promising method to 
reduce cell damage following stress is to reduce Aβ production. The goal of this thesis was 
to test stress induced toxicity following treatment with iBSec1 and DIA10D to reduce Aβ 
on AD cell lines.  
 Results showed a concentration dependent increase in ROS and decrease in cell 
viability following addition of hydrogen peroxide as oxidative stress. Addition of iBSec1 
and DIA10D to cells showed statistically significant reduction of ROS in both unstressed 
and stressed 7PA2. Cell viability assay verified these results, showing that higher 
concentration of hydrogen peroxide is needed to reduce cell viability in 7PA2 cells treated 
with iBSec1 and DIA10D. However, expression of DIA10D in regular CHO cells showed 
inconclusive result for ROS and no difference in cell viability compared to non-transfected 
CHO cells. These results show that both iBSec1 and DIA10D effectively blocked stress-
induced toxicity in AD cell models and are promising therapeutics for treatment of 
Alzheimer’s disease.  
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4.2. Future work 
 Based on results, future work includes: 
1. Quantification of Aβ in supernatant and cell lysate samples: Intracellular and 
extracellular Aβ can be measured using sandwich ELISA or western blot. Total 
Aβ can be probed using 6E10 monoclonal antibody while oligomeric Aβ can 
be probed using A4 and E1 scFv (Kasturirangan et al., 2012).  
2. Transfection and toxicity study of SH-SY5Y cells with DIA10D: SH-SY5Y is 
a brain derived neuroblastoma cell line that can be differentiated into 
cholinergic cell. Addition of hydrogen peroxide to undifferentiated SH-SY5Y 
cell has been reported to increase Aβ production. In-vitro neuroprotection of 
DIA10D can be tested by toxicity test of both undifferentiated and cholinergic 
SH-SY5Y. 
3. In-vivo study of iBSec1 and DIA10D: Effect of iBSec1 and DIA10D can also 
be tested in AD mouse model; this includes their ability to cross the blood brain 
barrier, delivery into brain, and neuroprotection in AD mouse model.  
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